FTC Seeks More Information on the $16.5B Novo-Catalent Deal, Leading to Another Delay – MedCity News
Novo Holdings’ $16.5 billion planned acquisition of Catalent is facing another delay. Just weeks after Novo decided to resubmit its application to the FTC, the agency is seeking more information about the deal. This move has triggered a second 30-day delay in the antitrust review process.